Celltrion's Truxima shows safety, efficacy in post-marketing study

Truxima has been gaining market share in both regions, reaching 23.6% in Europe and 27.6% in the US

Celltrion's Truxima shows safety, efficacy in post-marketing study
Jeong-Min Nam 1
2023-02-16 10:41:35 peux@hankyung.com
Bio & Pharma

South Korean biopharmaceutical company Celltrion Inc. reported on Wednesday that its biosimilar drug Truxima (rituximab), a generic version of Roche Holding AG's cancer drug Rituxan, has shown safety and efficacy in a post-marketing study involving 677 patients in Korea.

The study, published in the journal Expert Opinion on Biological Therapy, evaluated Truxima's use for several indications, including non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia, Wegener's granulomatosis, and microscopic polyangiitis.

The study found that Truxima had a similar safety profile and high response rate as the original drug based on data from 27 Korean centers between Nov. 2016 and Nov. 2020.

"We hope that these study results will serve as meaningful evidence for expanding the prescription of Truxima," said a Celltrion official. "We will continue to analyze the post-marketing clinical data and strive to provide patients with high-quality medicines."

Containing the active ingredient rituximab, Truxima was approved for sale in Korea in 2016, later receiving regulatory approvals in Europe and the US in 2017 and 2018, respectively.

The drug has been gaining market share in both regions, reaching 23.6% in Europe and 27.6% in the US as of the third quarter of 2022, according to Celltrion. The global market size of rituximab was estimated at $5.9 billion in 2021 by pharmaceutical market research company IQVIA.

Write to Jeong-Min Nam at peux@hankyung.com
##Celltrion Inc. Truxima Rituxan #korea celltrion truxima #truxima us europe #celltrion truxima sci

Celltrion Healthcare launches anti-cancer biosimilar Vegzelma in Japan

Celltrion Healthcare launches anti-cancer biosimilar Vegzelma in Japan

Celltrion's Vegzelma Celltrion Healthcare Co. Ltd. said on Thursday that it launched Vegzelma, a biosimilar to the anti-cancer drug Avastin (active ingredient: bevacizumab) in Japan.In September last year, Vegzelma obtained marketing approval for metastatic colorectal cancer, non-small cell lun

Celltrion increases its stake in British ADC developer Iksuda

Celltrion increases its stake in British ADC developer Iksuda

Celltrion's headquarters in Songdo, Korea Celltrion Inc. has secured an additional stake in the UK's antibody-drug conjugate (ADC) developer Iksuda Therapeutics.According to Celltrion on Wednesday, it acquired additional stakes in Iksuda in two ways, including Celltrion's recent direct investme

Celltrion applies for EMA approval of smaller dose formulation of Yuflyma

Celltrion applies for EMA approval of smaller dose formulation of Yuflyma

Celltrion's Yuflyma Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosimilar of Humira (active ingredient: adalimumab), an autoimmune disease treatment developed by AbbVie of the US.Currently, the So

Celltrion's Remsima receives approval in 100 countries in 10 years

Celltrion's Remsima receives approval in 100 countries in 10 years

Celltrion's Remsima South Korea's most valuable biopharmaceutical company Celltrion Inc. said on Tuesday that its antibody biosimilar Remsima (ingredient: infliximab) has been approved in more than 100 countries ten years after its first approval.Remsima is a TNF-alpha inhibitor that is used to

KOICA donates Celltrion's Herzuma to Ukraine

KOICA donates Celltrion's Herzuma to Ukraine

Herzuma, Celltrion's breast and gastric cancers treatment Celltrion Healthcare Co. said on Monday that Herzuma (ingredient name: Trastuzumab) was dispatched to patients in Ukraine by the Korea International Cooperation Agency (KOICA).The latest donation was led by KOICA at the Ukrainian governm
(* comment hide *}